INTENSITY THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Intensity Therapeutics, Inc. | ||
| Date: March 14, 2024 | By: | /s/ Lewis H. Bender |
|---|---|---|
| Lewis H. Bender | ||
| President, Chief Executive Officer and Chairman | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Lewis H. Bender | President, Chief Executive Officer and Chairman | March 14, 2024 |
| Lewis H. Bender | (principal executive officer) | |
| /s/ Joseph Talamo | Chief Financial Officer | March 14, 2024 |
| Joseph Talamo | (principal financial officer) | |
| /s/ John Wesolowski | Principal Accounting Officer and Controller | March 14, 2024 |
| John Wesolowski | (principal accounting officer) | |
| /s/ Daniel Donovan | Director | March 14, 2024 |
| Daniel Donovan | ||
| /s/ Dr. Emer Leahy | Director | March 14, 2024 |
| Dr. Emer Leahy | ||
| /s/ Dr. Mark A. Goldberg | Director | March 14, 2024 |
| Dr. Mark A. Goldberg | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.